1-4 of 4
Paul Tapang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Free
Elizabeth A. Punnoose, Joel D. Leverson, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont, Nguyen Tan, Amy Young, Michael Mitten, Ellen Ingalla, Walter C. Darbonne, Anatol Oleksijew, Paul Tapang, Peng Yue, Jason Oeh, Leslie Lee, Sophie Maiga, Wayne J. Fairbrother, Martine Amiot, Andrew J. Souers, Deepak Sampath
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (5): 1132–1144.
https://doi.org/10.1158/1535-7163.MCT-15-0730
Published: 05 May 2016
View article titled, Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Open the PDF for Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models in another window
Includes: Supplementary data
Journal Articles

Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.

Free
Michael L. Curtin, Robin Heyman, Robin R. Frey, Niru B. Soni, Patick A. Marcotte, Lori J. Pease, Keith B. Glaser, Terrance J. Magoc, Paul Tapang, Daniel H. Albert, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Zhiwen Guan, Ruth L. Martin, Kent D. Stewart, Chris Tse, Steven K. Davidsen, Michael R. Michaelides
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C202.
https://doi.org/10.1158/1535-7163.TARG-11-C202
Published: 12 November 2011
View article titled, Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.
Journal Articles

Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.

Free
Keith B. Glaser, Junling Li, Patrick A. Marcotte, Terrance J. Magoc, Jun Guo, David R. Reuter, Paul Tapang, Ru-Qi Wei, Lori J. Pease, Mai H. Bui, Zehan Chen, Robin R. Frey, Eric F. Johnson, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Michael L. Curtin, Cherrie K. Donawho, Michael R. Michaelides, Chris Tse, Steven K. Davidsen, Daniel H. Albert
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A239.
https://doi.org/10.1158/1535-7163.TARG-11-A239
Published: 12 November 2011
View article titled, Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.
Journal Articles

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

Free
Daniel H. Albert, Paul Tapang, Terrance J. Magoc, Lori J. Pease, David R. Reuter, Ru-Qi Wei, Junling Li, Jun Guo, Peter F. Bousquet, Nayereh S. Ghoreishi-Haack, Baole Wang, Gail T. Bukofzer, Yi-Chun Wang, Jason A. Stavropoulos, Kresna Hartandi, Amanda L. Niquette, Nirupama Soni, Eric F. Johnson, J. Owen McCall, Jennifer J. Bouska, Yanping Luo, Cherrie K. Donawho, Yujia Dai, Patrick A. Marcotte, Keith B. Glaser, Michael R. Michaelides, Steven K. Davidsen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (4): 995–1006.
https://doi.org/10.1158/1535-7163.MCT-05-0410
Published: 28 April 2006
View article titled, Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor
Open the PDF for Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor in another window